Expertise in
6
conditions

Dr. Erwin L. Robin

Oncology
Illinois Bone And Joint Institute LLC
10110 Donald S Powers Dr Ste 101B, 
Munster, IN 
Expertise in
6
conditions
Illinois Bone And Joint Institute LLC
10110 Donald S Powers Dr Ste 101B, 
Munster, IN 

Overview

Erwin Robin is an Oncologist practicing medicine in Munster, Indiana.

Dr. Robin is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Non-Hodgkin Lymphoma, Gastric Lymphoma, and Chronic Familial Neutropenia.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 4 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Illinois Bone and Joint Institute LLC
10110 Donald S Powers Dr Ste 101B, Munster, IN 46321

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Other, Drug
Study Drugs: mFOLFIRINOX, Ramucirumab
Study Phase: Phase 2
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
View 3 Less Clinical Trials

2 Total Publications

Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).
Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 08, 2022
Similar Doctors
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
 (24.5 miles away)
888-824-0200
Languages Spoken:
English, Greek, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rush University Medical Center

1725 W Harrison St Ste 1010, 
Chicago, IL 
 (24.1 miles away)
312-563-2320
Languages Spoken:
English
See accepted insurances

Philip Bonomi is an Oncologist practicing medicine in Chicago, Illinois. Dr. Bonomi is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Expertise in
20
conditions
Dr. Peter A. Riedell
Hematology | Oncology
Expertise in
20
conditions
Dr. Peter A. Riedell
Hematology | Oncology
Referral may be required

UChicago Medicine Duchossois Center For Advanced Medicine - Hyde Park

5758 S. Maryland Ave., 
Chicago, IL 
 (17.6 miles away)
888-824-0200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Riedell is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Riedell is highly rated in 20 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Riedell is board certified in Practicing Since2013 and Hematology Medical Oncology. Dr. Riedell is currently accepting new patients.

Frequently Asked Questions about Dr. Erwin L. Robin

How do I make an appointment with Dr. Erwin L. Robin?

You can book an appointment with Dr. Erwin L. Robin by calling their office at 219-924-8178. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Erwin L. Robin a top-rated expert for Pleuropulmonary Blastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Erwin L. Robin is classified as an Advanced expert for Pleuropulmonary Blastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Erwin L. Robin specialize in?

While Dr. Erwin L. Robin is a Oncology, they have specific expertise in Pleuropulmonary Blastoma, Non-Hodgkin Lymphoma, and Gastric Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Erwin L. Robin participate in research or clinical trials?

Yes. Dr. Erwin L. Robin has published 2 articles and abstracts on conditions like Pleuropulmonary Blastoma. You can view a list of Dr. Erwin L. Robin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Erwin L. Robin accept my insurance?

Dr. Erwin L. Robin accepts most major insurance plans, including Cigna and Health Care Services Corporation. We recommend calling the office directly at 219-924-8178 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Robin's expertise for a condition
ConditionClose
      View All 57 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile